Počet záznamů: 1
CDK9 activity is critical for maintaining MDM4 overexpression in tumor cells
- 1.
SYSNO ASEP 0533489 Druh ASEP J - Článek v odborném periodiku Zařazení RIV J - Článek v odborném periodiku Poddruh J Článek ve WOS Název CDK9 activity is critical for maintaining MDM4 overexpression in tumor cells Tvůrce(i) Štětková, M. (CZ)
Growková, K. (CZ)
Fojtík, P. (CZ)
Valčíková, B. (CZ)
Palušová, V. (CZ)
Verlande, A. (CZ)
Jorda, Radek (UEB-Q) ORCID, RID
Kryštof, Vladimír (UEB-Q) RID, ORCID
Hejret, V. (CZ)
Alexiou, P. (CZ)
Rotrekl, V. (CZ)
Uldrijan, S. (CZ)Celkový počet autorů 12 Číslo článku 754 Zdroj.dok. Cell Death & Disease. - : Springer - ISSN 2041-4889
Roč. 11, č. 9 (2020)Poč.str. 14 s. Jazyk dok. eng - angličtina Země vyd. GB - Velká Británie Klíč. slova DEPENDENT KINASE INHIBITOR ; RNA-POLYMERASE-II ; NUCLEAR ACCUMULATION Vědní obor RIV FD - Onkologie a hematologie Obor OECD Genetics and heredity (medical genetics to be 3) Způsob publikování Open access Institucionální podpora UEB-Q - RVO:61389030 UT WOS 000573087600002 EID SCOPUS 85091053112 DOI 10.1038/s41419-020-02971-3 Anotace The identification of the essential role of cyclin-dependent kinases (CDKs) in the control of cell division has prompted the development of small-molecule CDK inhibitors as anticancer drugs. For many of these compounds, the precise mechanism of action in individual tumor types remains unclear as they simultaneously target different classes of CDKs – enzymes controlling the cell cycle progression as well as CDKs involved in the regulation of transcription. CDK inhibitors are also capable of activating p53 tumor suppressor in tumor cells retaining wild-type p53 gene by modulating MDM2 levels and activity. In the current study, we link, for the first time, CDK activity to the overexpression of the MDM4 (MDMX) oncogene in cancer cells. Small-molecule drugs targeting the CDK9 kinase, dinaciclib, flavopiridol, roscovitine, AT-7519, SNS-032, and DRB, diminished MDM4 levels and activated p53 in A375 melanoma and MCF7 breast carcinoma cells with only a limited effect on MDM2. These results suggest that MDM4, rather than MDM2, could be the primary transcriptional target of pharmacological CDK inhibitors in the p53 pathway. CDK9 inhibitor atuveciclib downregulated MDM4 and enhanced p53 activity induced by nutlin-3a, an inhibitor of p53-MDM2 interaction, and synergized with nutlin-3a in killing A375 melanoma cells. Furthermore, we found that human pluripotent stem cell lines express significant levels of MDM4, which are also maintained by CDK9 activity. In summary, we show that CDK9 activity is essential for the maintenance of high levels of MDM4 in human cells, and drugs targeting CDK9 might restore p53 tumor suppressor function in malignancies overexpressing MDM4. Pracoviště Ústav experimentální botaniky Kontakt David Klier, knihovna@ueb.cas.cz, Tel.: 220 390 469 Rok sběru 2021 Elektronická adresa http://doi.org/10.1038/s41419-020-02971-3
Počet záznamů: 1